CASI vs CAN

For growth investors, Canaan Inc.

(CAN) is the stronger pick with 96. 7% revenue growth year-over-year, versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). Analysts rate Canaan Inc. (CAN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Canaan Inc.

(CAN) delivered a total return of -92. 0%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: CAN returned -89. 6% versus CASI's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 12β versus Canaan Inc. 's 4. 41β — meaning CAN is approximately -3697% more volatile than CASI relative to the S&P 500. On balance sheet safety, Canaan Inc. (CAN) carries a lower debt/equity ratio of 13% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Canaan Inc.

(CAN) is pulling ahead at 96. 7% versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). On earnings-per-share growth, the picture is similar: Canaan Inc. grew EPS 51. 1% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Over a 3-year CAGR, CASI leads at -1. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Canaan Inc.

(CAN) is the more profitable company, earning -39. 7% net margin versus -137. 6% for CASI Pharmaceuticals, Inc. — meaning it keeps -39. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CAN leads at -21. 2% versus -138. 8% for CASI. At the gross margin level — before operating expenses — CASI leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, CASI (31.

1% yield) pays a dividend. CAN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Canaan Inc. (CAN) carries a higher beta of 4. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CASI: -98. 9%, CAN: -89. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CASI (Healthcare) and CAN (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CASI is a small-cap income-oriented stock; CAN is a small-cap high-growth stock. CASI pays a dividend while CAN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.